Natural history of castration-resistant nonmetastatic prostate cancer: Secondary analyses of a multicenter randomized controlled trial.

Natural History ◽

Controlled Trial ◽

Randomized Controlled ◽

Castration Resistant ◽

Multicenter Randomized Controlled Trial ◽

History Of ◽

Secondary Analyses

Can atorvastatin with metformin change the natural history of prostate cancer as characterized by molecular, metabolomic, imaging and pathological variables? A randomized controlled trial protocol

Contemporary Clinical Trials ◽

10.1016/j.cct.2016.06.014 ◽

2016 ◽

Vol 50 ◽

pp. 16-20 ◽

Cited By ~ 2

Author(s):

Matthew J. Roberts ◽

John W. Yaxley ◽

Geoffrey D. Coughlin ◽

Troy R.J. Gianduzzo ◽

Rachel C. Esler ◽

...

Keyword(s):

Prostate Cancer ◽

Natural History ◽

Controlled Trial ◽

Trial Protocol ◽

Randomized Controlled ◽

History Of

Re: Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer

European Urology ◽

10.1016/j.eururo.2010.06.020 ◽

2010 ◽

Vol 58 (3) ◽

pp. 466 ◽

Cited By ~ 1

Author(s):

David S. Finley ◽

Frederic Pouliot ◽

Allan Pantuck

Keyword(s):

Prostate Cancer ◽

Overall Survival ◽

Survival Analysis ◽

Controlled Trial ◽

Randomized Controlled ◽

Castration Resistant ◽

Overall Survival Analysis ◽

Targeted Immunotherapy

A multicenter, randomized, controlled trial comparing the occurrence of major adverse cardiovascular events (MACEs) in patients (pts) with prostate cancer (pc) and cardiovascular disease (CVD) receiving degarelix (GnRH receptor antagonist) or leuprolide (GnRH receptor agonist).

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.tps5101 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. TPS5101-TPS5101 ◽

Cited By ~ 1

Author(s):

Susan F. Slovin ◽

Chiara Melloni ◽

Samreen Mansor-Lefebvre ◽

Anders Neijber ◽

Matthew Roe

Keyword(s):

Prostate Cancer ◽

Cardiovascular Disease ◽

Multicenter Randomized Controlled Trial

Cardiovascular Events ◽

Receptor Agonist ◽

Controlled Trial ◽

Gnrh Receptor ◽

Major Adverse Cardiovascular Events ◽

Randomized Controlled ◽

Goserelin Acetate with or without Antiandrogen or Estrogen in the Treatment of Patients with Advanced Prostate Cancer: A Multicenter, Randomized, Controlled Trial in Japan

Japanese Journal of Clinical Oncology ◽

10.1093/jjco/29.11.562 ◽

1999 ◽

Vol 29 (11) ◽

pp. 562-570 ◽

Cited By ~ 21

Author(s):

T. Kotake ◽

M. Usami ◽

H. Akaza ◽

K. Koiso ◽

Y. Homtna ◽

...

Keyword(s):

Prostate Cancer ◽

Advanced Prostate Cancer ◽

Controlled Trial ◽

Randomized Controlled ◽

Multicenter Randomized Controlled Trial ◽

Goserelin Acetate

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer

Yearbook of Oncology ◽

10.1016/s1040-1741(10)79581-6 ◽

2011 ◽

Vol 2011 ◽

pp. 110-111

Author(s):

C.A. Lawton

Keyword(s):

Prostate Cancer ◽

Overall Survival ◽

Survival Analysis ◽

Controlled Trial ◽

Randomized Controlled ◽

Castration Resistant ◽

Overall Survival Analysis ◽

Targeted Immunotherapy

Decreased biochemical progression in patients with castration‑resistant prostate cancer using a novel mefenamic acid anti‑inflammatory therapy: A randomized controlled trial

Oncology Letters ◽

10.3892/ol.2020.11509 ◽

2020 ◽

Author(s):

Jos� Guzman‑Esquivel ◽

Martha Mendoza‑Hernandez ◽

Daniel Tiburcio‑Jimenez ◽

Oscar Avila‑Zamora ◽

Josuel Delgado‑Enciso ◽

...

Keyword(s):

Prostate Cancer ◽

Mefenamic Acid ◽

Controlled Trial ◽

Randomized Controlled ◽

Castration Resistant ◽

Biochemical Progression ◽

Anti Inflammatory

Abiraterone acetate plus LHRH therapy versus abiraterone acetate while sparing LHRH therapy in patients with progressive, metastatic and chemotherapy-naïve, castration-resistant prostate cancer (SPARE): study protocol for a randomized controlled trial

Trials ◽

10.1186/s13063-017-2195-x ◽

2017 ◽

Vol 18 (1) ◽

Cited By ~ 5

Author(s):

Carsten-Henning Ohlmann ◽

Michelle Jäschke ◽

Peter Jaehnig ◽

Susane Krege ◽

Jürgen Gschwend ◽

...

Keyword(s):

Prostate Cancer ◽

Study Protocol ◽

Controlled Trial ◽

Abiraterone Acetate ◽

Randomized Controlled ◽

Castration Resistant ◽

Lhrh Therapy

Easipro3 – Enhancing Satisfaction With Prostate Cancer Treatment Decision With The Mobile Health Program Prostana: A Multicenter Randomized Controlled Trial

Value in Health ◽

10.1016/j.jval.2017.08.598 ◽

2017 ◽

Vol 20 (9) ◽

pp. A504 ◽

Cited By ~ 1

Author(s):

S Vosgerau ◽

D Urbanski ◽

P Kollenbach ◽

M Schöne ◽

M Gedamke ◽

...

Keyword(s):

Prostate Cancer ◽

Multicenter Randomized Controlled Trial

Cancer Treatment ◽

Mobile Health ◽

Health Program ◽

Controlled Trial ◽

Treatment Decision ◽

Prostate Cancer Treatment ◽

Randomized Controlled ◽

1244 THE NATURAL HISTORY OF NOCTURIA AMONG MEN ALLOCATED TO PLACEBO: RESULTS FROM A RANDOMIZED CONTROLLED TRIAL WITH ONE YEAR FOLLOW-UP

The Journal of Urology ◽

10.1016/j.juro.2012.02.1562 ◽

2012 ◽

Vol 187 (4S) ◽

Author(s):

Kari A.O. Tikkinen ◽

Jari Haukka ◽

Rufus Cartwright ◽

Camille P. Vaughan ◽

Alayne D. Markland ◽

...

Keyword(s):

Natural History ◽

Controlled Trial ◽

Randomized Controlled ◽

History Of ◽

One Year

Transperineal prostate brachytherapy, using I-125 seed with or without adjuvant androgen deprivation, in patients with intermediate-risk prostate cancer: study protocol for a phase III, multicenter, randomized, controlled trial

BMC Cancer ◽

10.1186/1471-2407-10-572 ◽

2010 ◽

Vol 10 (1) ◽

Cited By ~ 22

Author(s):

Kenta Miki ◽

Takayoshi Kiba ◽

Hiroshi Sasaki ◽

Masahito Kido ◽

Manabu Aoki ◽

...

Keyword(s):

Prostate Cancer ◽

Controlled Trial ◽

Phase Iii ◽

Prostate Brachytherapy ◽

Intermediate Risk ◽

Randomized Controlled ◽

Multicenter Randomized Controlled Trial ◽

Risk Prostate Cancer ◽

Prostate Cancer Study